Full Press Release Details
ImmuCell Announces Preliminary, Unaudited Sales
PORTLAND, Maine - April 9, 2024 - ImmuCell
Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops,
manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle,
today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024.
| Preliminary, Unaudited Total Sales Results: | ||||||||||||||||
| 2024 | 2023 | $ Increase | % Increase | |||||||||||||
| During the Three-Month Periods Ended March 31, | $ | 7.3 million | $ | 3.4 million | $ | 3.8 million | 111 | % | ||||||||
| During the Twelve-Month Periods Ended March 31, | $ | 21.3 million | $ | 16.0 million | $ | 5.3 million | 33 | % |
Total sales during the three-month period ended March 31, 2024 were
111% more than the comparable period ended March 31, 2023. Total sales during the three-month period ended March 31, 2024 were 42% more
than the $5.1 million in sales recorded during the three-month period ended December 31, 2023. Total sales during the twelve-month period
ended March 31, 2024 were 33% more than the twelve-month period ended March 31, 2023.
"The $7.3 million in total product sales achieved during the
first quarter of 2024 is an all-time quarterly sales record for us," commented Michael F. Brigham, President and CEO of ImmuCell.
"This high mark in sales exceeds our next best quarter of $6 million during the first quarter of 2022 by 21%, or $1.3 million."
As the work to increase production output to meet demand continues,
the backlog of orders was worth approximately $9.1 million as of March 31, 2024, which is a small decrease from approximately $9.4 million
as of December 31, 2023 but still a large increase from approximately $2.5 million as of December 31, 2022.
"In addition, we continue to work to achieve FDA approval to
commercialize Re-Tain ," Mr. Brigham concluded. "We expect a response from the FDA to our third submission
of the CMC Technical Section no later than May 2024."
Since the first quarter of 2020, the Company has been providing a
preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to provide this prompt, preliminary
report on product sales until further notice going forward.
The Company is planning to host a conference call on Friday, May 10, 2024 at 9:00 AM ET to discuss the unaudited financial results
for the quarter ended March 31, 2024. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412)
317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until May 17, 2024 at (877) 344-7529 (toll
free) or (412) 317-0088 (international), utilizing replay access code #2581533. Investors are encouraged to review the Company's
Corporate Presentation slide deck that provides an overview of the Company's business and is available under the "Investors"
tab of the Company's website at www.immucell.com, or by request to the Company. An updated version of the slide deck was made available
under the "Investors" tab of the Company's website on April 2, 2024.
ImmuCell Corporation's (Nasdaq:
ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef
cattle. ImmuCell manufactures and markets First Defense , providing Immediate Immunity to newborn
dairy and beef calves, and is in the late stages of developing Re-Tain , a novel treatment for subclinical mastitis
in dairy cows with a no milk discard claim that provides an alternative to traditional antibiotics. Press releases and other information
about the Company are available at: http://www.immucell.com.
Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor
This Press Release and the statements to be made
in the related conference call referenced herein contain "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to
historical or current facts, and will often include words such as "expects", "may", "anticipates",
"aims", "intends", "would", "could", "should", "will", "plans",
"believes", "estimates", "targets", "projects", "forecasts", "seeks"
and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans
and strategies for our business; projections of future financial or operational performance; the timing and outcome of pending or anticipated
applications for regulatory approvals; future demand for our products; the scope and timing of ongoing and future product development
work and commercialization of our products; future costs of product development efforts; the expected efficacy of new products; estimates
about the market size for our products; future market share of and revenue generated by current products and products still in development;
our ability to increase production output and reduce costs of goods sold per unit; the adequacy of our own manufacturing facilities or
those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the impacts of
backlogs on customer relationships; the efficacy or timeline to complete our contamination remediation efforts; the likelihood, severity
or impact of future contamination events; the robustness of our manufacturing processes and related technical issues; estimates about
our production capacity, efficiency and yield; future regulatory requirements relating to our products; future expense ratios and margins;
the effectiveness of our investments in our business; anticipated changes in our manufacturing capabilities and efficiencies; our effectiveness
in competing against competitors within both our existing and our anticipated product markets; projections about depreciation expense
and its impact on income for book and tax return purposes; our ability to convert the backlog of orders into sales; and any other statements
that are not historical facts. These statements are intended to provide management's current expectation of future events as of
the date of this press release, are based on management's estimates, projections, beliefs and assumptions as of the date hereof;
and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company's
actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these
forward-looking statements, including, but not limited to, those risks and uncertainties relating to: difficulties or delays in development,
testing, regulatory approval, production and marketing of our products (including the First Defense product line
and Re-Tain ), competition within our anticipated product markets, customer acceptance of our new and existing products,
product performance, alignment between our manufacturing resources and product demand (including the consequences of backlogs), uncertainty
associated with the timing and volume of customer orders as we come out of a prolonged backlog, adverse impacts of supply chain disruptions
on our operations and customer and supplier relationships, commercial and operational risks relating to our current and planned expansion
of production capacity, and other risks and uncertainties detailed from time to time in filings we make with the Securities and Exchange
Commission (SEC), including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such
statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to
various factors. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that
we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or otherwise.